Intellia Depreciation vs End Period Cash Flow Analysis

NTLA Stock  USD 12.10  0.08  0.66%   
Intellia Therapeutics financial indicator trend analysis is infinitely more than just investigating Intellia Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intellia Therapeutics is a good investment. Please check the relationship between Intellia Therapeutics Depreciation and its End Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

Depreciation vs End Period Cash Flow

Depreciation vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intellia Therapeutics Depreciation account and End Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Intellia Therapeutics' Depreciation and End Period Cash Flow is 0.57. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Intellia Therapeutics, assuming nothing else is changed. The correlation between historical values of Intellia Therapeutics' Depreciation and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Intellia Therapeutics are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Depreciation i.e., Intellia Therapeutics' Depreciation and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.57
Relationship DirectionPositive 
Relationship StrengthWeak

Depreciation

Depreciation indicates how much of Intellia Therapeutics value has been used up. For tax purposes Intellia Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Intellia Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

End Period Cash Flow

Most indicators from Intellia Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.37, whereas Issuance Of Capital Stock is forecasted to decline to about 410.5 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses300.9M510.3M551.6M579.1M
Cost Of Revenue6.9M7.6M9.0M8.5M

Intellia Therapeutics fundamental ratios Correlations

0.921.01.00.780.90.9-0.5-0.820.790.710.880.890.770.99-0.630.940.990.780.881.00.890.98-0.630.750.84
0.920.90.920.620.971.0-0.45-0.950.660.680.850.940.910.9-0.550.860.90.870.980.90.990.92-0.550.710.71
1.00.90.990.80.90.89-0.45-0.810.830.660.90.90.740.99-0.660.950.980.790.880.990.880.97-0.660.760.87
1.00.920.990.760.90.9-0.49-0.830.780.70.880.890.760.99-0.620.940.980.780.880.990.890.98-0.620.750.84
0.780.620.80.760.70.62-0.62-0.570.860.70.660.660.640.8-0.780.80.840.610.650.820.610.78-0.780.640.79
0.90.970.90.90.70.99-0.38-0.970.720.610.890.970.920.88-0.580.870.890.951.00.90.990.89-0.580.70.73
0.91.00.890.90.620.99-0.4-0.970.670.640.860.950.910.88-0.550.850.880.910.990.891.00.9-0.550.710.69
-0.5-0.45-0.45-0.49-0.62-0.38-0.40.31-0.29-0.96-0.21-0.29-0.55-0.530.57-0.46-0.57-0.15-0.37-0.52-0.38-0.580.57-0.4-0.41
-0.82-0.95-0.81-0.83-0.57-0.97-0.970.31-0.62-0.55-0.8-0.93-0.94-0.790.51-0.81-0.81-0.94-0.99-0.81-0.98-0.830.51-0.68-0.56
0.790.660.830.780.860.720.67-0.29-0.620.450.720.70.540.8-0.710.840.830.690.680.830.650.78-0.710.670.74
0.710.680.660.70.70.610.64-0.96-0.550.450.440.530.720.72-0.630.650.760.390.610.720.620.78-0.630.540.55
0.880.850.90.880.660.890.86-0.21-0.80.720.440.960.660.88-0.470.780.850.880.860.880.870.8-0.470.580.87
0.890.940.90.890.660.970.95-0.29-0.930.70.530.960.830.88-0.50.810.870.950.960.890.960.85-0.50.60.78
0.770.910.740.760.640.920.91-0.55-0.940.540.720.660.830.74-0.610.770.780.830.930.770.910.81-0.610.660.52
0.990.90.990.990.80.880.88-0.53-0.790.80.720.880.880.74-0.650.930.980.740.860.990.870.98-0.650.740.88
-0.63-0.55-0.66-0.62-0.78-0.58-0.550.570.51-0.71-0.63-0.47-0.5-0.61-0.65-0.8-0.65-0.48-0.57-0.66-0.52-0.671.0-0.76-0.6
0.940.860.950.940.80.870.85-0.46-0.810.840.650.780.810.770.93-0.80.920.770.860.940.840.95-0.80.890.76
0.990.90.980.980.840.890.88-0.57-0.810.830.760.850.870.780.98-0.650.920.760.871.00.870.98-0.650.730.83
0.780.870.790.780.610.950.91-0.15-0.940.690.390.880.950.830.74-0.480.770.760.940.780.920.74-0.480.590.63
0.880.980.880.880.651.00.99-0.37-0.990.680.610.860.960.930.86-0.570.860.870.940.880.990.88-0.570.70.68
1.00.90.990.990.820.90.89-0.52-0.810.830.720.880.890.770.99-0.660.941.00.780.880.880.98-0.660.750.85
0.890.990.880.890.610.991.0-0.38-0.980.650.620.870.960.910.87-0.520.840.870.920.990.880.89-0.520.680.68
0.980.920.970.980.780.890.9-0.58-0.830.780.780.80.850.810.98-0.670.950.980.740.880.980.89-0.670.780.78
-0.63-0.55-0.66-0.62-0.78-0.58-0.550.570.51-0.71-0.63-0.47-0.5-0.61-0.651.0-0.8-0.65-0.48-0.57-0.66-0.52-0.67-0.76-0.6
0.750.710.760.750.640.70.71-0.4-0.680.670.540.580.60.660.74-0.760.890.730.590.70.750.680.78-0.760.57
0.840.710.870.840.790.730.69-0.41-0.560.740.550.870.780.520.88-0.60.760.830.630.680.850.680.78-0.60.57
Click cells to compare fundamentals

Intellia Therapeutics Account Relationship Matchups

Intellia Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets334.3M676.3M1.3B1.5B1.3B686.6M
Other Current Liab13.3M19.9M34.2M60.9M48.4M50.8M
Total Current Liabilities35.6M64.3M125.8M126.6M115.2M64.2M
Total Stockholder Equity269.9M527.1M1.0B1.2B1.1B548.5M
Other Liab16.1M51.4M63.5M44.0M50.6M38.1M
Net Tangible Assets269.9M612.1M1.2B1.4B1.6B1.7B
Property Plant And Equipment Net37.1M55.1M100.1M161.0M148.1M155.5M
Net Debt(38.9M)(120.7M)(49.4M)(392.8M)(111.4M)(117.0M)
Retained Earnings(300.9M)(435.1M)(703.0M)(1.2B)(1.7B)(1.6B)
Accounts Payable3.9M10.5M9.7M5.2M7.5M5.3M
Cash57.2M160.0M123.4M523.5M226.7M203.4M
Non Current Assets Total44.8M79.0M525.2M303.3M302.6M317.8M
Non Currrent Assets Other2.9M22.0M87.7M73.0M83.9M88.1M
Other Assets2.9M4.7M4.8M15.7M18.1M19.0M
Cash And Short Term Investments279.7M597.4M1.1B1.3B912.2M566.6M
Common Stock Shares Outstanding47.2M56.0M70.9M77.0M88.8M50.5M
Liabilities And Stockholders Equity334.3M676.3M1.3B1.5B1.3B686.6M
Non Current Liabilities Total28.8M85.0M128.4M158.0M135.6M73.9M
Other Current Assets5.1M14.3M37.2M20.4M49.7M52.1M
Other Stockholder Equity570.5M962.2M1.7B2.4B2.7B2.8B
Total Liab64.4M149.3M254.2M284.5M250.8M138.1M
Property Plant And Equipment Gross37.1M55.1M126.2M194.2M188.0M197.4M
Total Current Assets289.5M597.4M769.3M1.2B998.3M541.2M
Accumulated Other Comprehensive Income261K1K(2.6M)(7.5M)(2.3M)(2.4M)
Property Plant Equipment37.1M15.9M21.0M27.9M32.1M18.1M
Current Deferred Revenue12.7M22.5M63.8M43.8M22.1M29.3M
Net Receivables4.6M2.1M2.0M3.8M36.5M38.3M
Capital Surpluse570.5M962.2M1.7B2.4B2.8B2.9B
Retained Earnings Total Equity(300.9M)(435.1M)(703.0M)(1.2B)(1.1B)(1.0B)
Short Term Investments222.5M437.4M625.3M669.1M685.5M398.1M
Net Invested Capital269.9M527.1M1.0B1.2B1.1B738.8M
Net Working Capital253.8M552.3M643.5M1.1B883.1M633.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.45)
Revenue Per Share
0.449
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.28)
Return On Equity
(0.52)
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.